Alendronate Sodium Tablet
Product Images NDC 64980-340

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 64980-340). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Alendronate Fig1)

A line graph showing the cumulative incidence (%) of hip fractures over 36 months in patients with radiographic vertebral fractures. It compares two groups: placebo (dashed line) and Alendronate Sodium (solid line), with lower incidence observed in the Alendronate Sodium group throughout the study.*

FDA Label Image

Package Label-principal Display Panel (70 mg Blister Carton (4 Unit-of-use))

Carton label for Alendronate Sodium Tablets, USP 70 mg, oral tablets by Rising Pharma Holdings, Inc. The label states the tablets are for once weekly use and include 4 tablets per package. Instructions for pharmacists to dispense a medication guide are visible, along with dosage warnings and directions for use. The label also displays the NDC number 64980-342-14 and usage instructions for removing tablets from the blister pack.*

FDA Label Image

Figure 2 (Alendronate Fig2)

Bar chart titled 'Osteoporosis Treatment Studies in Postmenopausal Women' showing mean percent increase in bone mineral density (BMD) at three years with Alendronate 10 mg/day. The chart compares increases in BMD at three sites: Lumbar Spine, Femoral Neck, and Trochanter, with separate bars for U.S. and multinational study populations.*

FDA Label Image

Figure 3 (Alendronate Fig3)

A dual-line chart titled 'Osteoporosis Treatment Studies in Postmenopausal Women' showing the time course of the effect of Alendronate 10 mg/day versus placebo on lumbar spine bone mineral density (BMD) percent change from baseline over 36 months. The left graph depicts a U.S. study and the right, a multinational study. Both show BMD improvements over time with Alendronate 10 mg compared to placebo, measured as mean percent change ± standard error.*

FDA Label Image

Figure 4 (Alendronate Fig4)

Two bar charts titled 'Osteoporosis Prevention Studies in Postmenopausal Women' show change in Bone Mineral Density (BMD) from baseline over 2-year and 3-year studies. The charts compare mean percentage BMD change with Alendronate 5 mg/day versus placebo across lumbar spine, femoral neck, trochanter, and total body sites.*

FDA Label Image

Figure 5 (Alendronate Fig5)

A bar graph showing the percentage increase in bone mineral density (BMD) at the lumbar spine, femoral neck, and trochanter in glucocorticoid-treated patients after one year of taking 5 mg/day Alendronate. Data compares results from U.S. and multinational studies, with BMD increases indicated with error bars for standard error.*

FDA Label Image

Figure 6 (Alendronate Fig6)

A line graph depicting the effect of Alendronate 40 mg/day versus placebo and Etidronate 400 mg/day on serum alkaline phosphatase levels over a 6-month period in Paget's Disease of Bone. The y-axis shows mean percentage change from baseline serum alkaline phosphatase with standard error, and the x-axis shows time in months. Separate lines represent placebo, Etidronate, and Alendronate from two studies (multinational and U.S.).*

FDA Label Image

Package Label-principal Display Panel (10 mg (30 Tablets Bottle))

Alendronate Sodium Tablets, USP 10 mg oral tablets label by Rising Pharma Holdings, Inc. The label states 30 tablets per container with dispensing instructions for pharmacists and dosage information for 10 mg daily use. The product is distributed by Rising Pharmaceuticals, Inc., made in India, and includes storage instructions and barcode.*

FDA Label Image

Package Label-principal Display Panel (10 mg (100 Tablets Bottle))

Label for Alendronate Sodium Tablets USP 10 mg by Rising Pharmaceuticals, Inc. The label indicates 100 tablets per container with a prescription-only designation. Active ingredient content per tablet is equivalent to 10 mg alendronic acid. Storage instructions and distribution information for Rising Pharmaceuticals in Saddle Brook, NJ are provided, along with a barcode and revision date of 07/2018.*

FDA Label Image

Package Label-principal Display Panel (35 mg Blister Carton (4 Unit-of-use))

Packaging label for Alendronate Sodium Tablets USP 35 mg oral tablets by Rising Pharma Holdings, Inc. The label states "Once Weekly" use and contains 4 tablets. It includes a medication guide advisory for pharmacists and dosage instructions on the inner panels. The label features the NDC 64980-341-14 and specifies the product is Rx only.*

FDA Label Image

Chemical Structure (Alendronate Str)

Chemical structure of Alendronate Sodium, showing its molecular arrangement including amino, hydroxyl, phosphonate groups, and associated sodium and water molecules (3H2O).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.